Status:

COMPLETED

Dapagliflozin in Type 1 Diabetes

Lead Sponsor:

Medical University Innsbruck

Collaborating Sponsors:

Medical University of Graz

University of Bern

Conditions:

Fasting Glucose

Glucose Excursion

Eligibility:

MALE

18-60 years

Phase:

PHASE4

Brief Summary

Dapagliflozin is a highly selective, reversible and potent inhibitor of the sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for its use as a treatment option in type 2...

Eligibility Criteria

Inclusion

  • Type 1 diabetes mellitus (duration of disease at least 5 years)
  • C-peptide concentration \< 0.2µg/l
  • male sex
  • aged 18 to 60 years
  • Body Mass Index 20 - 25 kg/m2
  • no measurable, clinically relevant ketonuria

Exclusion

  • insufficient venous status on both forearms
  • renal and/or hepatic insufficiency (including microalbuminuria and/or albumin/creatinin-ratio)
  • history of cancer
  • intake of medication and/or substances capable to influence insulin sensitivity within the last 3 months prior to study inclusion
  • alcohol- and/or drug abuse, nicotine consumption \> 5 cigarettes / 24h
  • brittle-diabetes
  • history of severe hypoglycemia, defined as the need for foreign assistance independent of actual blood glucose concentration measured
  • history or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the participant to give written informed consent, would pose a risk to subject safety, or interfere with the study evaluation, procedures or completion.

Key Trial Info

Start Date :

August 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 8 2017

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT02211742

Start Date

August 1 2014

End Date

February 8 2017

Last Update

March 16 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University Innsbruck, Department of Internal Medicine I

Innsbruck, Tyrol, Austria, 6020

Dapagliflozin in Type 1 Diabetes | DecenTrialz